FDA grants fast track designation to Sanofi’s SAR446597
SAR446597 is a one-time intravitreal gene therapy treatment for the treatment of geographic atrophy
Related Articles
Taking the Hurt Out of Ocular Trauma Management: A Survival Guide for New Attendings
Let’s break down how to confidently handle ocular trauma as a young attending. No need to feel like you’re being thrown into the deep end,…
Small-aperture IOL improves vision in eyes with previous refractive surgery
LOS ANGELES — In patients who previously underwent refractive surgery or corneal inlay implantation, the small-aperture IC-8 Apthera IOL demonstrated positive vision outcomes, Robert E.…
Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470
Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other territories of the…
AAVantgarde Bio receives IND clearance for AAVB-039
AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.
2025 Archive – Retina Today
Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging,…
2024 SUMMER SYMPOSIUM – Women in Ophthalmology
Women in Ophthalmology is pleased to invite you to attend our 2024 Summer Symposium, which will take place at THE OMNI LA COSTA RESORT &…
Corneal Clouding in a 74-Year-Old Man
A man aged 74 years presented with painless blurry vision in the right eye. Examination revealed a granular white opacity and prominent blood vessels in…
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration
This cohort study conducted in Ontario, Canada, evaluates the risk of developing neovascular age-related macular degeneration associated with the use of glucagon-like peptide-1 receptor agonists…
OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.
Refractive Innovation in Private Practice – Eyetube
Neda Shamie, MD, sits down with George O. Waring IV, MD, FACS, for a conversation about his journey from academic medicine to founding the Waring…
